Minerva Surgical has launched a complete suite of minimally invasive devices and website to support healthcare practitioners in treating Abnormal Uterine Bleeding.
It is estimated that one-third of outpatient visits to the gynecologist are for AUB, and AUB accounts for more than 70 per cent of all gynecologic consults in the perimenopausal and post-menopausal years.
This common condition often results in a hysterectomy due to benign causes if not treated.
Dave Clapper, President & CEO, Minerva Surgical, said, “AUB holds women hostage. Their personal and professional quality of life suffers significantly, and the financial burden is crushing.”
Clapper added: “Our best-in-class devices are a leap forward in treatment, but we also commit to elevate awareness of AUB in our communities. We are excited to do our part to eliminate this horrible condition that too often results in unnecessary hysterectomies.”
Hysterectomy is the second most common surgery performed on reproductive-age women in the United States, after cesarean section. Nearly 68 per cent of the 400,000 hysterectomies performed each year are due to benign conditions that involve abnormal uterine bleeding, uterine fibroids and endometriosis.
The conservatively estimated annual costs of AUB were approximately $1 billion direct costs to women and $12 billion indirect costs to the community.
Minerva Surgical, is comprised of a newly minted suite of minimally invasive tools. They include the Minerva Endometrial Ablation System, the all-in-one tissue removal system that transforms the way physicians remove uterine fibroids, Genesys HTA Endometrial Ablation System and the Resectr device for the removal of endometrial polyps in the medical office setting.
(With inputs from The OnLook News Research Bureau)